LGALS1 and arthritic joint disease: In recent years, the essential role of recombinant galectin-1 in the control of inflammation has been widely demonstrated in experimental studies for treatment of various diseases, including autoimmune encephalomyelitis (12, 13), arthritis (23, 24), hepatitis (25), autoimmune diabetes (26, 27), and ulcerative colitis (28).